Max Quastel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Max Quastel has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Andrew J. McMichael
Centre for Immuno-Oncology, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
5 shared publications - Geraldine M. Gillespie
Nuffield Department of Medicine Centre for Immuno‐Oncology University of Oxford Oxford UK
5 shared publications - Simon Brackenridge
Nuffield Department of Clinical Medicine, University of Oxford
3 shared publications - Bas W. A. Peeters
Nuffield Department of Medicine, University of Oxford, Oxford, UK
2 shared publications Daniel Rozbesky
Department of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic
2 shared publications- Edith Yvonne Jones
Division of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK
2 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (11)
eHLAstic reveals an extended canonical and non-canonical HLA-E immunopeptidome in human cancers
- 4 November 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (11)
Open AccesseHLAstic reveals an extended canonical and non-canonical HLA-E immunopeptidome in human cancers
- Open Access
- 7 August 2026
- Published by Elsevier in SSRN Electronic Journal
eHLAstic Reveals An Extended the Canonical and Non-Canonical HLA-E Immunopeptidome in Human Cancers
Human leukocyte antigen-E (HLA-E) is a non-classical MHC class I molecule with restricted polymorphism, offering a putative path to off-the-shelf therapies applicable across entire patient cohorts. Yet, the search for suitable cancer-restricted HLA-E targets has been hindered by low expression levels and limited knowledge on the wider HLA-E peptide repertoire, which is largely assumed restricted to a small set of canonical leader sequence-derived ligands. To address this, we developed eHLAstic, a dedicated HLA-E binding predictor, which improved the precision of HLA-E ligand discovery by almost threefold compared with existing approaches. Using eHLAstic and orthogonal biochemical binding validation, we identified and validated 31 previously unrecognised canonical and non-canonical HLA-E-associated peptides, including six cancer-restricted ligands detected in acute lymphoblastic and acute myeloid leukaemia but not in healthy blood or bone marrow cells. Many of the newly identified HLA-E ligands were shared across individuals with diverse HLA backgrounds. Moreover, most newly identified ligands were not confined to haematological malignancies but were also detected across multiple solid cancers. All but one of the non-canonical ligands were detected exclusively in cancer-associated samples and not in healthy cells or tissues. These findings redefine the HLA-E ligandome in healthy and cancer cells and uncover a previously unrecognized repertoire of canonical and non-canonical HLA-E ligands with potential for immune recognition and a promising route for therapeutic targeting.
- 7 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccesseHLAstic Reveals An Extended the Canonical and Non-Canonical HLA-E Immunopeptidome in Human Cancers
Human leukocyte antigen-E (HLA-E) is a non-classical MHC class I molecule with restricted polymorphism, offering a putative path to off-the-shelf therapies applicable across entire patient cohorts. Yet, the search for suitable cancer-restricted HLA-E targets has been hindered by low expression levels and limited knowledge on the wider HLA-E peptide repertoire, which is largely assumed restricted to a small set of canonical leader sequence-derived ligands. To address this, we developed eHLAstic, a dedicated HLA-E binding predictor, which improved the precision of HLA-E ligand discovery by almost threefold compared with existing approaches. Using eHLAstic and orthogonal biochemical binding validation, we identified and validated 31 previously unrecognised canonical and non-canonical HLA-E-associated peptides, including six cancer-restricted ligands detected in acute lymphoblastic and acute myeloid leukaemia but not in healthy blood or bone marrow cells. Many of the newly identified HLA-E ligands were shared across individuals with diverse HLA backgrounds. Moreover, most newly identified ligands were not confined to haematological malignancies but were also detected across multiple solid cancers. All but one of the non-canonical ligands were detected exclusively in cancer-associated samples and not in healthy cells or tissues. These findings redefine the HLA-E ligandome in healthy and cancer cells and uncover a previously unrecognized repertoire of canonical and non-canonical HLA-E ligands with potential for immune recognition and a promising route for therapeutic targeting.
- Open Access
Identification and Structural Characterization of a mutant KRAS-G12V specific TCR restricted by HLA-A3
Summary: Mutations in KRAS are some of the most common across multiple cancer types and are thus attractive targets for therapy. Recent studies demonstrated that mutant KRAS generates immunogenic neoantigens that can be targeted in adoptive T cell therapy in metastatic diseases. To expand mutant KRAS specific immunotherapies, it is critical to identify additional HLA-I allotypes that can present KRAS neoantigens and their cognate T cell receptors (TCR). Here, we identified a murine TCR specific to a KRAS-G12V neoantigen ( 7 VVVGAVGVGK 16 ) using a vaccination approach with transgenic mice expressing the common HLA-I allotype, HLA-A*03:01 (HLA-A3). This TCR demonstrated exquisite specificity for mutant G12V and not Wt KRAS peptides. To investigate the molecular basis for neoantigen recognition by This TCR, we determined its structure in complex with HLA-A3(G12V). G12V-TCR CDR3β and CDR1 β formed a hydrophobic pocket to interact with p6 Val of the G12V but not Wt KRAS peptide. To improve the tumor sensitivity of This TCR, we designed rational substitutions to improve TCR:HLA-A3 contacts. Two substitutions exhibited modest improvements in TCR binding to HLA-A3 (G12V), but did not sufficiently improve T cell sensitivity for further clinical development. Our study provides mechanistic insight into how TCRs detect neoantigens and reveals the challenges in targeting KRAS-G12V mutations. [203]
Open AccessIdentification and Structural Characterization of a mutant KRAS-G12V specific TCR restricted by HLA-A3
Summary: Mutations in KRAS are some of the most common across multiple cancer types and are thus attractive targets for therapy. Recent studies demonstrated that mutant KRAS generates immunogenic neoantigens that can be targeted in adoptive T cell therapy in metastatic diseases. To expand mutant KRAS specific immunotherapies, it is critical to identify additional HLA-I allotypes that can present KRAS neoantigens and their cognate T cell receptors (TCR). Here, we identified a murine TCR specific to a KRAS-G12V neoantigen ( 7 VVVGAVGVGK 16 ) using a vaccination approach with transgenic mice expressing the common HLA-I allotype, HLA-A*03:01 (HLA-A3). This TCR demonstrated exquisite specificity for mutant G12V and not Wt KRAS peptides. To investigate the molecular basis for neoantigen recognition by This TCR, we determined its structure in complex with HLA-A3(G12V). G12V-TCR CDR3β and CDR1 β formed a hydrophobic pocket to interact with p6 Val of the G12V but not Wt KRAS peptide. To improve the tumor sensitivity of This TCR, we designed rational substitutions to improve TCR:HLA-A3 contacts. Two substitutions exhibited modest improvements in TCR binding to HLA-A3 (G12V), but did not sufficiently improve T cell sensitivity for further clinical development. Our study provides mechanistic insight into how TCRs detect neoantigens and reveals the challenges in targeting KRAS-G12V mutations. [203]
- 30 June 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 8 (84) , eabl8881
HLA-E–restricted SARS-CoV-2–specific T cells from convalescent COVID-19 patients suppress virus replication despite HLA class Ia down-regulation
Pathogen-specific CD8 + T cell responses restricted by the nonpolymorphic nonclassical class Ib molecule human leukocyte antigen E (HLA-E) are rarely reported in viral infections. The natural HLA-E ligand is a signal peptide derived from classical class Ia HLA molecules that interact with the NKG2/CD94 receptors to regulate natural killer cell functions, but pathogen-derived peptides can also be presented by HLA-E. Here, we describe five peptides from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that elicited HLA-E–restricted CD8 + T cell responses in convalescent patients with coronavirus disease 2019. These T cell responses were identified in the blood at frequencies similar to those reported for classical HLA-Ia–restricted anti–SARS-CoV-2 CD8 + T cells. HLA-E peptide–specific CD8 + T cell clones, which expressed diverse T cell receptors, suppressed SARS-CoV-2 replication in Calu-3 human lung epithelial cells. SARS-CoV-2 infection markedly down-regulated classical HLA class I expression in Calu-3 cells and primary reconstituted human airway epithelial cells, whereas HLA-E expression was not affected, enabling T cell recognition. Thus, HLA-E–restricted T cells could contribute to the control of SARS-CoV-2 infection alongside classical T cells.
- 30 June 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 8 (84) , eabl8881
HLA-E–restricted SARS-CoV-2–specific T cells from convalescent COVID-19 patients suppress virus replication despite HLA class Ia down-regulation
Pathogen-specific CD8 + T cell responses restricted by the nonpolymorphic nonclassical class Ib molecule human leukocyte antigen E (HLA-E) are rarely reported in viral infections. The natural HLA-E ligand is a signal peptide derived from classical class Ia HLA molecules that interact with the NKG2/CD94 receptors to regulate natural killer cell functions, but pathogen-derived peptides can also be presented by HLA-E. Here, we describe five peptides from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that elicited HLA-E–restricted CD8 + T cell responses in convalescent patients with coronavirus disease 2019. These T cell responses were identified in the blood at frequencies similar to those reported for classical HLA-Ia–restricted anti–SARS-CoV-2 CD8 + T cells. HLA-E peptide–specific CD8 + T cell clones, which expressed diverse T cell receptors, suppressed SARS-CoV-2 replication in Calu-3 human lung epithelial cells. SARS-CoV-2 infection markedly down-regulated classical HLA class I expression in Calu-3 cells and primary reconstituted human airway epithelial cells, whereas HLA-E expression was not affected, enabling T cell recognition. Thus, HLA-E–restricted T cells could contribute to the control of SARS-CoV-2 infection alongside classical T cells.
- 1 June 2023
- Published by Springer Nature in Nature Immunology
- Vol. 24 (7) , 1087-1097
HLA class I signal peptide polymorphism determines the level of CD94/NKG2–HLA-E-mediated regulation of effector cell responses
Human leukocyte antigen (HLA)-E binds epitopes derived from HLA-A, HLA-B, HLA-C and HLA-G signal peptides (SPs) and serves as a ligand for CD94/NKG2A and CD94/NKG2C receptors expressed on natural killer and T cell subsets. We show that among 16 common classical HLA class I SP variants, only 6 can be efficiently processed to generate epitopes that enable CD94/NKG2 engagement, which we term ‘functional SPs’. The single functional HLA-B SP, known as HLA-B/−21M, induced high HLA-E expression, but conferred the lowest receptor recognition. Consequently, HLA-B/−21M SP competes with other SPs for providing epitope to HLA-E and reduces overall recognition of target cells by CD94/NKG2A, calling for reassessment of previous disease models involving HLA-B/−21M. Genetic population data indicate a positive correlation between frequencies of functional SPs in humans and corresponding cytomegalovirus mimics, suggesting a means for viral escape from host responses. The systematic, quantitative approach described herein will facilitate development of prediction algorithms for accurately measuring the impact of CD94/NKG2–HLA-E interactions in disease resistance/susceptibility.
- 1 June 2023
- Published by Springer Nature in Nature Immunology
- Vol. 24 (7) , 1087-1097
HLA class I signal peptide polymorphism determines the level of CD94/NKG2–HLA-E-mediated regulation of effector cell responses
Human leukocyte antigen (HLA)-E binds epitopes derived from HLA-A, HLA-B, HLA-C and HLA-G signal peptides (SPs) and serves as a ligand for CD94/NKG2A and CD94/NKG2C receptors expressed on natural killer and T cell subsets. We show that among 16 common classical HLA class I SP variants, only 6 can be efficiently processed to generate epitopes that enable CD94/NKG2 engagement, which we term ‘functional SPs’. The single functional HLA-B SP, known as HLA-B/−21M, induced high HLA-E expression, but conferred the lowest receptor recognition. Consequently, HLA-B/−21M SP competes with other SPs for providing epitope to HLA-E and reduces overall recognition of target cells by CD94/NKG2A, calling for reassessment of previous disease models involving HLA-B/−21M. Genetic population data indicate a positive correlation between frequencies of functional SPs in humans and corresponding cytomegalovirus mimics, suggesting a means for viral escape from host responses. The systematic, quantitative approach described herein will facilitate development of prediction algorithms for accurately measuring the impact of CD94/NKG2–HLA-E interactions in disease resistance/susceptibility.
- Top Cited Papers
- 7 December 2022
- Published by Springer Nature in Nature
- Vol. 612 (7941) , 771-777
Autoimmunity-associated T cell receptors recognize HLA-B*27-bound peptides
Human leucocyte antigen B*27 (HLA-B*27) is strongly associated with inflammatory diseases of the spine and pelvis (for example, ankylosing spondylitis (AS)) and the eye (that is, acute anterior uveitis (AAU))1. How HLA-B*27 facilitates disease remains unknown, but one possible mechanism could involve presentation of pathogenic peptides to CD8+ T cells. Here we isolated orphan T cell receptors (TCRs) expressing a disease-associated public β-chain variable region–complementary-determining region 3β (BV9–CDR3β) motif2,3,4 from blood and synovial fluid T cells from individuals with AS and from the eye in individuals with AAU. These TCRs showed consistent α-chain variable region (AV21) chain pairing and were clonally expanded in the joint and eye. We used HLA-B*27:05 yeast display peptide libraries to identify shared self-peptides and microbial peptides that activated the AS- and AAU-derived TCRs. Structural analysis revealed that TCR cross-reactivity for peptide–MHC was rooted in a shared binding motif present in both self-antigens and microbial antigens that engages the BV9–CDR3β TCRs. These findings support the hypothesis that microbial antigens and self-antigens could play a pathogenic role in HLA-B*27-associated disease.
- 7 December 2022
- Published by Springer Nature in Nature
- Vol. 612 (7941) , 771-777
Top Cited PapersAutoimmunity-associated T cell receptors recognize HLA-B*27-bound peptides
Human leucocyte antigen B*27 (HLA-B*27) is strongly associated with inflammatory diseases of the spine and pelvis (for example, ankylosing spondylitis (AS)) and the eye (that is, acute anterior uveitis (AAU))1. How HLA-B*27 facilitates disease remains unknown, but one possible mechanism could involve presentation of pathogenic peptides to CD8+ T cells. Here we isolated orphan T cell receptors (TCRs) expressing a disease-associated public β-chain variable region–complementary-determining region 3β (BV9–CDR3β) motif2,3,4 from blood and synovial fluid T cells from individuals with AS and from the eye in individuals with AAU. These TCRs showed consistent α-chain variable region (AV21) chain pairing and were clonally expanded in the joint and eye. We used HLA-B*27:05 yeast display peptide libraries to identify shared self-peptides and microbial peptides that activated the AS- and AAU-derived TCRs. Structural analysis revealed that TCR cross-reactivity for peptide–MHC was rooted in a shared binding motif present in both self-antigens and microbial antigens that engages the BV9–CDR3β TCRs. These findings support the hypothesis that microbial antigens and self-antigens could play a pathogenic role in HLA-B*27-associated disease.
- Open Access
- 14 June 2022
- Published by Elsevier in Cell Reports
- Vol. 39 (11) , 110959
Primary and secondary functions of HLA-E are determined by stability and conformation of the peptide-bound complexes
- 14 June 2022
- Published by Elsevier in Cell Reports
- Vol. 39 (11) , 110959
Open AccessPrimary and secondary functions of HLA-E are determined by stability and conformation of the peptide-bound complexes
- 19 May 2022
- Published by Springer Nature in Nature Reviews Immunology
- Vol. 22 (7) , 409
The CD58–CD2 axis in cancer immune evasion
- 19 May 2022
- Published by Springer Nature in Nature Reviews Immunology
- Vol. 22 (7) , 409
The CD58–CD2 axis in cancer immune evasion
- Open Access
- 28 March 2022
- Published by Springer Nature in Communications Biology
- Vol. 5 (1) , 1-17
Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity
The non-classical class Ib molecule human leukocyte antigen E (HLA-E) has limited polymorphism and can bind HLA class Ia leader peptides (VL9). HLA-E-VL9 complexes interact with the natural killer (NK) cell receptors NKG2A-C/CD94 and regulate NK cell-mediated cytotoxicity. Here we report the isolation of 3H4, a murine HLA-E-VL9-specific IgM antibody that enhances killing of HLA-E-VL9-expressing cells by an NKG2A+NK cell line. Structural analysis reveal that 3H4 acts by preventing CD94/NKG2A docking on HLA-E-VL9. Upon in vitro maturation, an affinity-optimized IgG form of 3H4 showes enhanced NK killing of HLA-E-VL9-expressing cells. HLA-E-VL9-specific IgM antibodies similar in function to 3H4 are also isolated from naïve B cells of cytomegalovirus (CMV)-negative, healthy humans. Thus, HLA-E-VL9-targeting mouse and human antibodies isolated from the naïve B cell antibody pool have the capacity to enhance NK cell cytotoxicity.
- 28 March 2022
- Published by Springer Nature in Communications Biology
- Vol. 5 (1) , 1-17
Open AccessMouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity
The non-classical class Ib molecule human leukocyte antigen E (HLA-E) has limited polymorphism and can bind HLA class Ia leader peptides (VL9). HLA-E-VL9 complexes interact with the natural killer (NK) cell receptors NKG2A-C/CD94 and regulate NK cell-mediated cytotoxicity. Here we report the isolation of 3H4, a murine HLA-E-VL9-specific IgM antibody that enhances killing of HLA-E-VL9-expressing cells by an NKG2A+NK cell line. Structural analysis reveal that 3H4 acts by preventing CD94/NKG2A docking on HLA-E-VL9. Upon in vitro maturation, an affinity-optimized IgG form of 3H4 showes enhanced NK killing of HLA-E-VL9-expressing cells. HLA-E-VL9-specific IgM antibodies similar in function to 3H4 are also isolated from naïve B cells of cytomegalovirus (CMV)-negative, healthy humans. Thus, HLA-E-VL9-targeting mouse and human antibodies isolated from the naïve B cell antibody pool have the capacity to enhance NK cell cytotoxicity.
- Open Access
- 1 December 2020
- Published by Portland Press Ltd. in Emerging Topics in Life Sciences
- Vol. 4 (4) , 423-433
Factors influencing the re-emergence of plague in Madagascar
Plague is an infectious disease found worldwide and has been responsible for pandemics throughout history. Yersinia pestis, the causative bacterium, survives in rodent hosts with flea vectors that also transmit it to humans. It has been endemic in Madagascar for a century but the 1990s saw major outbreaks and in 2006 the WHO described the plague as re-emerging in Madagascar and the world. This review highlights the variety of factors leading to plague re-emergence in Madagascar, including climate events, insecticide resistance, and host and human behaviour. It also addresses areas of concern for future epidemics and ways to mitigate these. Pinpointing and addressing current and future drivers of plague re-emergence in Madagascar will be essential to controlling future outbreaks both in Madagascar and worldwide.
- 1 December 2020
- Published by Portland Press Ltd. in Emerging Topics in Life Sciences
- Vol. 4 (4) , 423-433
Open AccessFactors influencing the re-emergence of plague in Madagascar
Plague is an infectious disease found worldwide and has been responsible for pandemics throughout history. Yersinia pestis, the causative bacterium, survives in rodent hosts with flea vectors that also transmit it to humans. It has been endemic in Madagascar for a century but the 1990s saw major outbreaks and in 2006 the WHO described the plague as re-emerging in Madagascar and the world. This review highlights the variety of factors leading to plague re-emergence in Madagascar, including climate events, insecticide resistance, and host and human behaviour. It also addresses areas of concern for future epidemics and ways to mitigate these. Pinpointing and addressing current and future drivers of plague re-emergence in Madagascar will be essential to controlling future outbreaks both in Madagascar and worldwide.